Top Page
Benchmark Holdings
(LSE:BMK)
Benchmark Holdings (BMK) vs. S&P 500 (SPY)
Benchmark Holdings Business Overview & Revenue Model
Benchmark Holdings Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 67.61M | 90.36M | 169.48M | 158.28M | 125.06M | 105.56M | Gross Profit |
| 25.62M | 43.95M | 86.75M | 83.13M | 65.58M | 54.96M | EBIT |
| -35.89M | -35.50M | -5.32M | -4.76M | -1.01M | -7.68M | EBITDA |
| 5.78M | 3.96M | 34.20M | 28.35M | 24.36M | 14.34M | Net Income Common Stockholders |
| -41.76M | -39.46M | -23.15M | -30.45M | -11.58M | -22.77M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 13.81M | 23.09M | 36.52M | 36.40M | 39.46M | 71.61M | Total Assets |
| 380.77M | 384.90M | 471.30M | 526.57M | 481.99M | 489.04M | Total Debt |
| 75.84M | 72.07M | 102.00M | 110.14M | 120.39M | 109.16M | Net Debt |
| 62.03M | 48.98M | 65.47M | 73.74M | 80.93M | 37.55M | Total Liabilities |
| 155.33M | 160.63M | 188.68M | 203.29M | 202.39M | 193.59M | Stockholders Equity |
| 219.74M | 218.26M | 276.40M | 313.40M | 271.71M | 289.13M |
| Cash Flow | Free Cash Flow | ||||
| -6.50M | -1.92M | 13.22M | -1.91M | -16.93M | -15.47M | Operating Cash Flow |
| -2.72M | 2.00M | 20.00M | 10.81M | 5.79M | -4.06M | Investing Cash Flow |
| -2.81M | -2.83M | -5.27M | -11.22M | -23.09M | 30.38M | Financing Cash Flow |
| -4.05M | -10.97M | -12.33M | -6.92M | -14.67M | 30.13M |
Benchmark Holdings Technical Analysis
Benchmark Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £169.01M | 4.65 | 33.70% | 2.04% | -0.17% | 2591.96% | |
62 Neutral | £42.35M | 64.43 | 0.80% | ― | -4.37% | ― | |
59 Neutral | £355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.82% | 16.45% | -0.47% | |
48 Neutral | £345.57M | ― | -369.20% | ― | 4.50% | 74.32% | |
45 Neutral | £167.58M | ― | ― | -16.14% | -68.06% |
Benchmark Holdings Corporate Events
Benchmark Holdings PLC announced that as of 30 April 2025, its issued share capital consists of 741,505,672 ordinary shares, all with voting rights. This figure has remained unchanged since the previous announcement on 31 March 2025, and shareholders can use this number to calculate their interest in the company. This stability in share capital indicates a steady state in the company’s financial structure, which could reassure investors and stakeholders about the company’s current market position.
Spark’s Take on GB:BMK Stock
According to Spark, TipRanks’ AI Analyst, GB:BMK is a Neutral.
Benchmark Holdings is grappling with significant financial difficulties characterized by declining revenue and persistent net losses. The technical indicators present a bearish outlook, compounded by an unattractive valuation due to negative earnings. Although corporate events highlight proactive debt management, they are insufficient to offset broader financial and market challenges. Strategic adjustments are crucial for improving the company’s financial health and growth prospects.
To see Spark’s full report on GB:BMK stock, click here.
Benchmark Holdings has announced the completion of its Green Bond redemption and repayment of its RCF, making the company debt-free. The company has also streamlined its corporate structure following the sale of its Genetics division, preparing for its next phase of operations. Details on the strategy for continuing business and return of capital are expected in May, signaling a strategic shift that could impact its market positioning and stakeholder interests.
Spark’s Take on GB:BMK Stock
According to Spark, TipRanks’ AI Analyst, GB:BMK is a Underperform.
Benchmark Holdings is facing significant financial difficulties, with declining revenue and net losses affecting its financial health. The stock’s technical indicators suggest a bearish trend, and the valuation is unattractive due to negative earnings. However, the proactive debt management through early bond redemption is a positive development but not enough to offset the overall negative outlook.
To see Spark’s full report on GB:BMK stock, click here.
Benchmark Holdings PLC announced its decision to exercise a call option to redeem all outstanding bonds from its senior unsecured bond issue, originally set to mature in September 2025. This strategic financial move, scheduled for completion by April 15, 2025, is expected to impact the company’s financial structure by addressing its debt obligations earlier than planned, potentially enhancing its market position and stakeholder confidence.
Benchmark Holdings has completed the sale of its genetics business to Starfish Bidco, a subsidiary of Novo Holdings, for an enterprise value of £260 million. This transaction is expected to yield gross cash proceeds of approximately £194 million, with net cash proceeds of about £107.5 million after debt repayments. The sale aligns with Benchmark’s strategic focus, and further details on the use of proceeds will be provided in mid-April.
Benchmark Holdings plc announced an update on its total voting rights, reporting an issued share capital of 741,505,672 ordinary shares as of March 31, 2025. This increase in shares, attributed to the routine exercise of options by employees, impacts the calculation for shareholders to notify changes in their interest in the company.
Benchmark Holdings reported its Q1 FY25 results, highlighting a transitional period as it moves towards completing the sale of its Genetics business and streamlining its operations. The company experienced a 30% decline in revenues from continuing operations compared to the previous year, primarily due to softness in shrimp markets and a change in product mix. Despite these challenges, the Health segment showed resilience, focusing on Salmosan® Vet. Benchmark is progressing with a new joint venture to develop a land-based model for Ectosan® Vet and CleanTreat®. The company plans to use proceeds from the Genetics sale to strengthen its balance sheet and return capital to shareholders.
Benchmark Holdings PLC, a company involved in the field of biotechnology and aquaculture, announced that its total issued share capital now consists of 741,455,200 ordinary shares, all with voting rights, as of 28 February 2025. This increase in shares is attributed to the routine exercise of options by current and former employees, impacting the total voting rights available, which shareholders can use to assess their interest in the company.